Journal
XENOBIOTICA
Volume 41, Issue 4, Pages 297-311Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/00498254.2010.545452
Keywords
BIBF 1120; pharmacokinetic profile; metabolism
Categories
Funding
- Boehringer Ingelheim
Ask authors/readers for more resources
The pharmacokinetics and metabolism of BIBF 1120, an oral triple angiokinase inhibitor targeting vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR), were studied in healthy male volunteers (n == 8) who had received a single oral dose of 100 mg [
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
